Physician profile
Anupama Ravi
NPI 1659557668
$11,017.99
in general payments reported to CMS, 2019-2025
33 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $726 · 2021: $1,718 · 2022: $1,759 · 2023: $1,364 · 2024: $2,159 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,488 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,488.31 |
| Education | $100.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,407.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,352.67 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,035.92 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $772.66 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $438.99 | 2023-2025 | Omvoh, Zepbound |
| Pfizer INC. | $412.36 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $405.83 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $373.89 | 2022-2025 | Dupixent |
| Celgene Corporation | $357.88 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $320.82 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $308.46 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $279.75 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $233.93 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $200.33 | 2024-2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $142.56 | 2025 | Iqirvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $117.08 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $116.08 | 2019-2024 | Linzess |
| Redhill Biopharma INC. | $111.98 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Ardelyx, INC. | $108.76 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $106.11 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.62 | 2023 | |
| Aimmune Therapeutics, INC. | $58.27 | 2024 | |
| Novo Nordisk INC | $53.26 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $42.04 | 2019-2022 | |
| Organon LLC | $41.04 | 2023 | Hadlima, Renflexis |
| Boston Scientific Corporation | $32.01 | 2020-2022 | |
| Ucb, INC. | $28.25 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $19.93 | 2022 | |
| Fresenius Kabi USA, LLC | $16.89 | 2024 | Idacio |
| Daiichi Sankyo INC. | $16.36 | 2021 | |
| Celltrion USA INC. | $15.19 | 2024 | Zymfentra |
| Vivus LLC | $15.08 | 2024 | Qsymia |
| Braintree Laboratories, INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupama Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.